|
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome Clinical research trials and Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome. Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome clinical trial. Test subjects typically receive the most expert healthcare available for their Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome  Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
For Condition: Lymphocytic Lymphoma,Mycosis Fungoides/Sezary Syndrome,Skin Cancer
Status: No longer recruiting
Sponsor(s): Robert H. Lurie Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
Details: OBJECTIVES: - Determine the response rate in patients with mycosis fungoides or Sezary syndrome treated with interleukin-2 (IL-2). - Determine the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive interleukin-2 subcutaneously for 4 consecutive days a week for 6 consecutive weeks. Treatment repeats every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response or stable disease continue treatment for 2 courses past best response. Patients who demonstrate a persistent partial response continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for survival. PROJECTED ACCRUAL: A total of 15-35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven mycosis fungoides or Sezary syndrome - Any stage - Measurable disease with 1 or more indicator lesions - Evaluable disease for erythrodermic patients only - At least 2 weeks since prior therapy, if documented progressive disease (PD) - At least 4 weeks since prior therapy, if best response achieved without clear evidence of PD PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 3 months Hematopoietic: - WBC at least 3,000/mm^3 - Absolute granulocyte count at least 1,000/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 2.2 mg/dL Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No New York Heart Association class III or IV heart disease - No cardiac pacemaker - No clinically significant peripheral venous insufficiency Other: - No other malignancy within the past 5 years except: - Treated squamous cell or basal cell skin cancer - Treated carcinoma in situ of the cervix - Surgically treated other cancer - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No active infection - HIV negative - No poorly controlled diabetes mellitus PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics Endocrine therapy: - No concurrent steroids Radiotherapy: - See Disease Characteristics - No concurrent radiotherapy Surgery: - Not specified Other: - No other concurrent proven or investigational antineoplastic therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
TimothyKuzel, Study Chair, Robert H. Lurie Cancer Center
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
Additional Information:
Study ID Numbers: CDR0000067726; NU-96H7,NCI-G00-1735
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005788
Other Skin Cancer Studies:
1. Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
2. Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
3. Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
4. TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
5. Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Related Studies:
Other Skin Cancer Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
|
|
|
|
|
|
|
|
